CRDL Cardiol Therapeutics Inc. Stock Quote

CRDL [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Canada

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	6.99%	Shs Outstand	59.30M	Perf Week	5.81%
Market Cap	119.57M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.00%	Shs Float	53.23M	Perf Month	-6.67%
Income	-35.00M	PEG	-	EPS next Q	-0.11	Inst Own	13.50%	Short Float	0.56%	Perf Quarter	-60.52%
Sales	0.08M	P/S	1518.21	EPS this Y	-30.50%	Inst Trans	-	Short Ratio	0.39	Perf Half Y	-16.32%
Book/sh	0.67	P/B	2.72	EPS next Y	32.80%	ROA	-130.00%	Target Price	-	Perf Year	-28.06%
Cash/sh	0.44	P/C	4.17	EPS next 5Y	-	ROE	-145.40%	52W Range	1.55 - 4.96	Perf YTD	-1.62%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-63.31%	Beta	-
Dividend %	-	Quick Ratio	12.00	Sales past 5Y	-	Gross Margin	-	52W Low	17.42%	ATR	0.17
Employees	14	Current Ratio	12.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.13	Volatility	13.58% 8.04%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-71.00%	Profit Margin	-	Rel Volume	0.49	Prev Close	1.98
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	765.28K	Price	1.82
Recom	1.50	SMA20	-2.91%	SMA50	-10.04%	SMA200	-35.13%	Volume	375,568	Change	-8.08%

Jan-19-22 07:27AM	Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board Newsfile -13.42%
Nov-05-21 09:18AM	Cardiol Therapeutics Announces Closing of US$50 Million Public Offering Newsfile
Nov-04-21 08:52AM	What You Need To Know About Cardiol Therapeutics Inc.'s (TSE:CRDL) Investor Composition Simply Wall St.
Nov-03-21 08:36AM	Cardiol Therapeutics Announces Pricing of Public Offering of Units CNW Group -25.22%
Nov-02-21 04:04PM	Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units CNW Group
Oct-25-21 07:27AM	Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis Newsfile
Oct-18-21 07:27AM	Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada Newsfile +10.94%
Sep-16-21 07:27AM	Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference Newsfile +9.67%
Sep-10-21 04:33PM	Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020 Newsfile
Sep-07-21 07:27AM	Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors Newsfile +11.26%
Aug-24-21 07:27AM	Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis Newsfile
Aug-19-21 06:52AM	When Will Cardiol Therapeutics Inc. (TSE:CRDL) Turn A Profit? Simply Wall St.

Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience